Tag Archives: Cdiff radio

Edmond A. Hooker, MD, DrPH and Nancy Foster, VP, Quality and Patient Safety Policy, American Hospital Association Discuss the CMS 2019 Inpatient Prospective Payment System (IPPS) on ‘C.diff. Spores and More’ Radio on July 3rd

Listen in on Tuesday, July 3rd at 1:00 p.m. ET

C. diff. Spores and More Global Broadcasting Network©

www.cdiffradio.com

Hosted by the C Diff Foundation   brought to you by VoiceAmerica and sponsored by Clorox Healthcare

Our guests Edmond A. Hooker, MD, DrPH and Nancy Foster, Vice President, Quality and Patient Safety Policy, American Hospital Association will be discussing the Centers for Medicare and Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services,  CMS 2019 Inpatient Prospective Payment System (IPPS) proposed rule – which includes proposals to de-duplicate measures across the five hospital quality reporting programs.

This special live broadcast discussion will be about the CMS’ recent proposals for Healthcare-associated infection (HAI) measures and to provide facts that will bring forth a better understanding of the proposed rule.

Guest Information:

Eddie Hooker, MD, DrPH,  is currently an Assistant Professor in the Department of Health Services Administration at Xavier University in Cincinnati, Ohio. He is also an Associate Clinical Professor in the Department of Emergency Medicine at the University of Louisville and at Wright State University. His areas of expertise include emergency medicine, epidemiology, health-services management, and public health.

Dr. Hooker received his BS degree from Hampden-Sydney College in Virginia. He earned his MD degree from Eastern Virginia Medical School. He then completed his residency training in Emergency Medicine at the University of Louisville. As a full-time faculty member at the University of Louisville from 1991 until 1996, Dr. Hooker served as an Associate Professor and Director of Resident Research. He was very active in brain trauma and stroke research. Dr. Hooker most recently practiced emergency medicine at a private hospital in Cincinnati, Ohio, where he was active cardiac research.   Since 2005, Dr. Hooker has been teaching in the Department of Health Services Administration at Xavier University. In the spring of 2007, Dr. Hooker earned his Doctorate in Public Health from the University of Kentucky.

Dr. Hooker continues to be active in emergency medicine and public-health research. He has authored more than 20 publications in leading emergency-medicine journals, published many book chapters, and continues to have an active research agenda. Dr. Hooker serves as an editor for Emedicine, an online clinical knowledge base. He is the medical advisor for Indian Hill Schools.

……………..

Nancy Foster is the Vice President for Quality and Patient Safety Policy at the American Hospital Association. In this role, she provides advice to public policymakers on legislation and regulations intended to improve patient safety and quality in America’s hospitals. Foster is the AHA’s point person at the National Quality Forum, the Hospital Workgroup of the Measures Application Partnership, and is the liaison to the Joint Commission’s Board, and represents hospital perspectives at many national meetings.

Prior to joining the AHA, Foster was the Coordinator for Quality Activities at the Agency for Healthcare Research and Quality (AHRQ). In this role, she was the principal staff person for the Quality Interagency Coordination Task Force, which brought Federal agencies with health care responsibilities together to coordinate their work and engage in projects to improve quality and safety. She also led the development of patient safety research agenda for AHRQ and managed a portfolio of quality and safety research grants in excess of $10 million.

She is a graduate of Princeton University and has completed graduate work at Chapman University and Johns Hopkins University. In 2000, she was chosen as an Excellence in Government Leadership Fellow.

C. diff. Spores and More ™“ spotlights world renowned topic experts, research scientists, healthcare professionals, organization representatives, C. diff. survivors, board members, and their volunteers who are all creating positive changes in the
C. diff.
community and more.

Through their interviews, the C Diff Foundation mission will connect, educate, and empower listeners worldwide.

Take our show on the go…………..download a mobile app today

www.voiceamerica.com/company/mobileapps

healthwellnesshealth (2)

  • This live broadcast will be archived in the ‘C.diff. Spores and More’ library and can be easily accessed at your leisure.   www.cdiffradio.com

C. diff. Spores and More, Join Us and Celebrate

www.cdiffradio.com

C. diff. Spores and More

Sponsored by Clorox Healthcare

Join us and Celebrate

with our 81,453 listeners – so far –  in Season III.

We thank our listeners joining us every

Tuesday at 10:00 a.m. PT / 1:00 p.m. ET

across the U.S. A. and to our listeners in

  • Australia
  • Brazil
  • Canada
  • China
  • France
  • Germany
  • India
  • Ireland
  • Israel
  • Japan
  • Malaysia
  • Peru
  • Russia
  • Spain
  • Switzerland
  • Taiwan
  • Trinidad
  • Ukraine
  • UK    and Across the Globe

We also extend our sincere gratitude to the guests who take time out of their busy

schedules to join us on each live broadcast.  Though their words of wisdom and

by sharing the most up-to-date information with us raises awareness in so

many important areas of healthcare.

 

Season III concludes on October 31, 2017

and we will be gearing up for

the 5th Annual International C. diff. Awareness Conference & Health EXPO taking

place on November 9th and 10th at the University of Nevada – Las Vegas.

For conference information please click on the link below.

https://cdifffoundation.org/2017cdiffconference/about-nov-2017-annual-conference/

 

Join us in Season IV when we return on January 9th, 2018

as we continue bringing you updates that are focused on, but not limited to,

C. difficile infection prevention, treatments, clinical trials, environmental safety

and much more.

Thank you again for listening and we wish you and your families improved health,

continued healing, and the best day — which you all deserve!

 

Home Health Care Information for Both Physicians and Patients

What is Home Health Care?

At its basic level, “home health care” means exactly what it sounds like – medical care provided in a patient’s home. Home health care can include a range of  care given by skilled medical professionals, including skilled nursing care, physical therapy, occupational therapy and speech therapy. Home health care can also include skilled, non-medical care, such as medical social services or assistance with daily personal activities provided by a highly qualified home health aide.

As the Medicare program describes, home health care is unique as a care setting not only because the care is provided in the home, but the care itself is “usually less expensive, more convenient, and just as effective” as care given in a hospital or skilled nursing facility.

When we say “home care” a common thought is senior care.  However; in  today’s society wellness draining diagnosis occur in every age group. Some of the more chronic, long-term illnesses greatly benefit from receiving home health care vs extended stays in acute care facilities and other health care in-patient services depending upon individual living situations and over-all health conditions.

Who qualifies for Home Health Care?

Each individual must contact their insurance provider to inquire about this skilled care provided within their home.  There may be co-pays per visit, limitations of the number of visits per episode and per calendar year, there may additional stipulations and should be understood by the patient and their families prior to discussing with a Medicare enrolled Physician.

To be eligible for Medicare home health services a patient must have Medicare Part A

and/or Part B.

To  be eligible for Home Health Care Services: (1)

  • Be confined to home.
  • Need Skilled Services.
  • Be Under the Care Of a Medicare -enrolled Physician.
  • Receive Services Under a Plan Of Care Established and Reviewed by a Physician and Have Had a Face-to-Face Encounter With a Physician or Allowed Non-Physician Practioner (NPP).  Care Must Be Furnished By or Under Arrangements Made by A Medicare-Participating Home  Home Health Agency (HHA).
  • Patient Eligibility—Confined to Home
    Section 1814(a) and Section 1835(a)
    of the Act specify that an

    individual is considered
    confined to the home” (homebound) if the following two criteria are met:
    First Criteria: One of the Following must be met:
    1. Because of illness or injury, the individual needs the aid of supportive devices such as crutches, canes, wheelchairs, and walkers; the use of special transportation; or the
    assistance of another person to leave their place of residence
    2.  Have a condition such that leaving his or her home is medically contraindicated.

    Second Criteria Both of the following must be met:
    1. There must exist a normal inability to leave home.
    2. Leaving home must require a considerable and taxing effort.

     

     

    Home Health Aids May Be Included In the Home Health Care Assessment and Assigned To Assist With Personal Care – Activities of Daily Living  (ADL’s), Bathing, Feeding, Dressing, and Walking.

    To learn more about Home Health Care Nursing and being treated in the home environment, listen to Linda Jablonski, MS, BSN, RN-BC – Director of Nursing Home Health.   Click on the C.diff. radio logo below to listen to the podcast.

    cdiffRadioLogoMarch2015

 

 

 

 

 

Sources:

(1) CMS  (article se1436)  https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/se1436.pdf

C. diff. Spores and More – CdiffRadio – Welcomes Guests; Dr. Guy de Bruyn,MD, Dr. Christian Felter,MD, and Dr. Patricia J. Pietrobon,Ph.D. of Sanofi Pasteur

SANOFI_Pasteur_RVB

Join us on Tuesday, March 1st as we discuss ——-

C. diff. Vaccine Update; Sanofi Pasteur’s Cdiffense”

Tuesday, March 1st — Live Broadcast Times

10 a.m. Pacific Time,,   11 a.m. Mountain Time,
12 p.m. Central Time,    1 p.m. Eastern Time

We invite you to  listen to the live broadcast and archived programs by clicking on the
Cdiff radio logo displayed below:

cdiffRadioLogoMarch2015

This episode we will introduce  Sanofi Pasteur, one of the leading vaccine manufacturers in the world, is in the midst of its Phase III clinical trial called Cdiffense to study its investigational vaccine to prevent Clostridium difficile infection (CDI).

The trial is now in more than 20 countries across 5 continents to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary, symptomatic CDI.

The investigational C. diff vaccine is designed to produce an immune response that targets the toxins generated by C. diff bacteria, which can cause inflammation of the gut. The investigative vaccine ultimately may help prevent a future infection from occurring. Volunteers for the study should be age 50 or older and planning an upcoming hospitalization or have had at least two hospital stays and have received systemic antibiotics in the past year.

For more information on the Cdiffense trial – Please visit www.Cdiffense.org 

Join Guests: 
Dr. Guy de Bruyn, MD  –  Director for Clinical Development at Sanofi Pasteur, overseeing a large phase III vaccine trial for the prevention of Clostridium difficile infection in some 19 countries on 5 continents around the world that started in the U.S. in 2013.

Dr. Christian Felter, MD  –  Associate VP, Global Medical Expert for Nosocomial Vaccines for Sanofi Pasteur based in Lyon, France. His focus is on their investigative Clostridium difficile vaccine. Dr. Felter has 11 years of experience in medical affairs roles in the US and Europe, covering therapeutic areas including Immunology, Rheumatology, and Infectious Diseases.

Dr. Patricia J. Freda Pietrobon, PhD  – Associate Vice President, Research & Development Sanofi Pasteur Dr. Patricia J. Freda Pietrobon, PhD, Associate Vice President, R&D, Sanofi Pasteur, has over 25 years of experience in the Vaccine & Diagnostic industries and more then 20 years in leadership roles focusing on research & development of new vaccines.

Join us as we introduce Sanofi Pasteur and discuss updates focused on

C. diff. Vaccine Update; Sanofi Pasteur’s Cdiffense

C. diff. Spores and More™  Global Broadcasting Network –  producing educational programs dedicated to  C. difficile Infections and more —  brought to you by VoiceAmerica and sponsored by Clorox Healthcare

 

*Please note – The C Diff Foundation does not endorse this product or any product and this posting is strictly for informational purposes only.

Dr. Nicholas Kartsonis Discusses Merck’s History In Infectious Disease and Their Ongoing Research Plus Some Of The Company’s Current Treatments, Including Dificid, To Address C. diff. Infections (CDI)

cdiffRadioLogoMarch2015                What’s new in the C Diff Foundation?

Let us introduce you to the first internet radio talk show dedicated to C. diff. and more……

C. diff. Spores and More”

 

UPCOMING SHOW:  TODAY ~ Tuesday, May 26th: 

 Dr. Nicholas Kartsonis;  Merck Research Laboratories (MRL)

Join us today, Tuesday, May 26th,  as our guest Dr. Nicholas Kartsonis , Associate Vice President of Clinical Research for Infectious Diseases for Merck Research Laboratories (MRL) and Section Head within MRL for antibiotics, antibacterials and cytomegalovirus  shares his time and discusses the past, present, and future contributions of Merck Research Laboratories.  

Dr. Kartsonis joined Merck Research Laboratories in February 2000 and has been actively involved in programs for new antibacterials, antifungals, anti-HIV, anti-CMV, and agents targeted against C. difficile infection.  Most recently, he has led the efforts to ensure the integration of the Cubist Pharmaceuticals clinical research portfolio within Merck. 

 Dr. Kartsonis will provide an overview of Merck’s current efforts to address the worldwide public health crisis posed by antimicrobial resistance, as well as the company’s history in infectious disease and antimicrobial stewardship. In addition, he will talk about the company’s current treatment for C. difficile and ongoing research efforts to address C. difficile infections (CDI).

http://www.voiceamerica.com/show/2441/c-diff-spores-and-more

 

We invite you to join us in listening to this exciting, new internet talk show that broadcasts live every Tuesday at the following times:

caralla-Promo-Health

 Click Image Above to Listen to Archived Shows

 


PT 11a,  MT 12p, CT 1p, ET  2 p

 

We are pleased to share C. diff. Spores and More” with you because, as advocates of C. diff., we know how important this cutting-edge new weekly radio show means for our Foundation’s community worldwide.

Hard Facts: Deaths and illnesses are much higher than reports have shown. Nearly half a million Americans suffered from Clostridium difficile (C. diff.) infections in a single year according to a study released today, February 25, 2015, by the Centers for Disease Control and Prevention (CDC).

• More than 100,000 of these infections developed among residents of U.S. nursing homes.

Approximately 29,000 patients died within 30 days of the initial diagnosis of a C. diff. infection. Of these 29,000 – 15,000 deaths were estimated to be directly related to a
C. diff. infection. Therefore; C. diff. is an important cause of infectious disease death in the U.S.
Previous studies indicate that C. diff. has become the most common microbial cause of Healthcare-Associated Infections found in U.S. hospitals driving up costs to $4.8 billion each year in excess health care costs in acute care facilities alone. Approximately
two-thirds of C. diff. infections were found to be associated with an inpatient stay in a health care facility, only 24% of the total cases occurred in patients while they were hospitalized. The study also revealed that almost as many cases occurred in nursing homes as in hospitals and the remainder of individuals acquired the
Healthcare-Associated infection, C. diff., recently discharged from a health care facility.

This new study finds that 1 out of every 5 patients with the Healthcare-Associated Infection (HAI), C. diff., experience a recurrence of the infection and 1 out of every 9 patients over the age of 65 diagnosed with a HAI – C. diff. infection died within 30 days of being diagnosed. Older Americans are quite vulnerable to this life-threatening diarrhea infection. The CDC study also found that women and Caucasian individuals are at an increased risk of acquiring a C. diff. infection. The CDC Director, Dr. Tom Frieden, MD, MPH said, “C. difficile infections cause immense suffering and death for thousands of Americans each year.” “These infections can be prevented by improving antibiotic prescribing and by improving infection control in the health care system. CDC hopes to ramp up prevention of this deadly infection by supporting State Antibiotic Resistance Prevention Programs in all 50 states.”

“This does not include the number of C. diff. infections taking place and being treated in other countries.”  “The  CDF supports hundreds of communities by sharing the CDF mission and    raising C. diff. awareness to healthcare professionals, individuals, patients, families,  and communities working towards a shared goal ~  witnessing a reduction of newly diagnosed            C. diff. cases by 2020 .”   ” The CDF Volunteers are greatly appreciated as they create positive changes sharing their time so generously worldwide aiding in the success of our mission and raising C. diff. awareness.”

C. diff. Spores and More” spotlights world renown topic experts, research scientists, healthcare professionals, organization representatives, C. diff. survivors, board members, and their volunteers who are all creating positive changes in the C. diff. community and more.

Through their interviews, the CDF mission will connect, educate, and empower many worldwide.

 

Questions received through the show page portal will be reviewed and addressed  by the show’s Medical Correspondent, Dr. Fred Zar, MD, FACP,  Dr. Fred Zar is a Professor of Clinical Medicine, Vice HeZarPhotoWebsiteTop (2)ad for Education in the Department of Medicine, and Program Director of the Internal Medicine Residency at the University of Illinois at Chicago.  Over the last two decades he has been a pioneer in the study of the treatment of Clostridium difficile disease and the need to stratify patients by disease severity.

 

Please join us Tuesdays in listening to the educational episodes of C. diff. Spores and More”

View the programs and radio information and access previous episodes available as a podcast by clicking on the link below:

www.voiceamerica.com/show/2441/c-diff-spores-and-more

 

Take our show on the go…………..download a mobile app today

http://www.voiceamerica.com/company/mobileapps

C Diff Foundation launches C. diff. Radio, “C. diff. Spores and More” on March 3rd, 2015

What’s new in the C Diff Foundation?  Let us introduce you to the first internet radio talk show dedicated to C. diff. and more……

C. diff. Spores and More”

We invite you to join us in listening to this exciing, new internet talk show when it debuts Tuesday, March 3rd, 2015 at the following times:

ET   2 – 3 p.m.,  CT 1 – 2 p.m.,  MT 12 – 1 p.m.,  PT 11 – 12 p.m.

We are so excited to share the debut of “C. diff. Spores and More” with you – not only because the C Diff Foundation, our Founding Executive Director –  Nancy C. Caralla, and Chairperson of Research and Development – Dr. Chandrabali Ghose, are introducing the first episode, but also because, as advocates of C. diff., we are very excited about what this cutting-edge new weekly radio show means for our Foundation’s community worldwide.

Fact: Deaths and illnesses are much higher than reports have shown. In March, 2012 the  CDC  said in a report that the C difficile infection kills 14,000 people a year. But that estimate is based on death certificates, which often don’t list the infection when patients die from complications, such as kidney failure.  Hospital billing data collected by the federal Agency for Healthcare Research and Quality shows that more than 9% of C. diff-related hospitalizations end in death — nearly five times the rate for other hospital stays. That adds up to more than 30,000 fatalities among the 347,000 C. diff hospitalizations in 2010. Thousands more patients are treated in nursing homes, clinics and doctors’ offices.

“We’re talking in the range of close to 500,000 total cases a year,” says Cliff McDonald, a C. diff expert and senior science adviser in the CDC’s Division of Healthcare Quality Promotion. And annual fatalities “may well be … as high as * 30,000.”

* AHRQ News and Numbers provides statistical highlights on the use and cost of health services and health insurance in the United States.

“This does not include the number of C. diff. infections taking place and being treated in other countries.”  “The  CDF supports hundreds of communities by sharing the CDF mission and    raising C. diff. awareness to healthcare professionals, individuals, patients, families,  and communities working towards a shared goal ~  witnessing a reduction of newly diagnosed                   C. diff. cases by 2020 .”   ” The CDF Volunteers are greatly appreciated as they create positive changes sharing their time so generously worldwide aiding in the success of our mission and raising C. diff. awareness.”

C. diff. Spores and More” will spotlight world renown topic experts, research scientists, healthcare professionals, organization representatives, C. diff. survivors, board members, and their volunteers who are all creating positive changes in the C. diff. community and more. Through their interviews, the CDF mission will connect, educate, and empower many in over 180 countries.

Please join us in listening to the first of many episodes of C. diff. Spores and More” debuting on Tuesday, March 3rd .

View the programs and radio information:

health.voiceamerica.com

Take our show on the go…………..download a mobile app today

http://www.voiceamerica.com/company/mobileapps

healthwellnesshealth (2)